Searched for
API HOLDINGS
Pharmeasy-parent’s loss narrows in Q1, revenue up 10%API Holdings, parent of PharmEasy and Thyrocare, narrowed its Q1 FY27 loss to Rs 29.6 crore from Rs 145.4 crore a year earlier, while reven...- ISM outlay faces currency pressure; ETSA 2026 Best on Campus, Comeback Kid nomineesA weak rupee has dragged down the dollar value of the India Semiconductor Mission subsidies. This and more in today’s ETtech Top 5.
- Pharmeasy founder says failure to deleverage was key reason for debt sagaSiddharth Shah’s comments came a day after API Holdings repaid Rs 1,050 crore of debt, becoming debt-free after years of pressure on its ba...
- At Beijing AI-themed bar, DeepSeek tokens come with the pintsAs AI enthusiasm sweeps across China, Song De opened AGI Bar, named after the concept of artificial general intelligence where AI systems s...
- Trump dwarfs his predecessors in the number of ultra-rich in his second White House, report showsDonald Trump appointed significantly more millionaires to his administration than prior presidents. Fifty-seven officials in his government...
- Pharmeasy parent clears Rs 1,050 crore debt, frees Thyrocare stake from pledgeThe debt repayment marks the latest step in API Holdings’ efforts to clean up its balance sheet after a difficult period struggling to rais...
- Chemical sector: Although long, there is a way around China trouble; combine 20 stocks to get your portfolio’s chemistry rightFor the chemicals sector, it all depends on a transformation that is still unfolding and will take years to play out. Backward-integration ...
- These large- and mid-cap stocks can give more than 25% return in 1 year, according to analystsLooking at what happens in the short term is important, as it does have an impact on stock prices. But also always keep an eye on the macro...
- Gland Pharma appoints Dr Reddy’s senior executive Deepak Sapra as CEOGland Pharma has appointed Deepak Sapra as its new chief executive officer, with his tenure set to begin on November 16, 2026, subject to h...
- ETtech Explainer: Meta's stop-start strategy for its open source AI modelsGlimmer, a 30-billion-parameter model, is much smaller than leading AI models from rivals and is designed for agentic tasks. It can run on ...
- Picking the right pharma stock is getting harder; so pick a portfolio: 20 stocks with -23% to +22% downside to upside potentialFor Indian pharma, the regulatory risk is still real. A US FDA inspection can still cause trouble. A plant making an important product or g...
- Indonesia government to take over state firm's stake in troubled China-funded high-speed railwayIndonesia's government will acquire a majority stake in the high-speed rail operator. This move aims to manage the project's outstanding lo...
- These large- and mid-cap stocks can give more than 25% return in 1 year, according to analystsThe price of crude oil is down again despite the escalating tensions in the Gulf region. That augurs well for markets. This does not mean t...
- GSTN puts proposed e-way bill changes on hold after industry feedbackGST Network has postponed two e-way bill system enhancements. These changes were scheduled for implementation starting August 1. Industry f...
- Tariff on generic drugs: Loud announcement, little consequence? 7 pharma stocks with upside potential of up to 31%The threat of a US tariff on Indian pharma is no longer a vague fear; or at least that is what President Trump wants us to believe. There i...
- Stock picks of the week: 6 stocks with consistent score improvement and upside potential of up to 26%The US-Iran war continues to create uncertainty for markets across the globe. But more so in India, due to the high correlation between ene...
- These large-, mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsWhen will the US-Iran war end? No one can answer that with any certainty. But whenever it ends, the probability is that volatility will con...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsAfter four days of relative outperformance, the Indian market is seemingly in trouble: Both the indices (the Nifty and Sensex) and market b...
- Dr Reddy’s shares crack 9% after weak Q1; these 3 brokerages slash their target pricesDr Reddy’s shares plunged 9% on Thursday after the drugmaker reported a weak Q1 FY27 performance, with net profit tumbling 69% year-on-year...
- Risk is integral to the market; but there are different kinds of risk: 6 mid-cap stocks with upside potential of up to 21%We are in uncertain and volatile times. Does that mean investors should just sit out the downturn? While that is an option, the better opti...
Load More
